1 |
NCT03016884 |
Recruiting |
Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients |
|
- Biological: Zostavax vaccine
|
Interventional |
Phase 4 |
- HaEmek Medical Center, Israel
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of patients with Injection site adverse reactions
- Number of patients with Hypersensitivity
- number of patients with Post vaccination non-injection-site zoster-like and varicella-like rashes
- (and 7 more...)
|
250 |
All |
50 Years and older (Adult, Senior) |
NCT03016884 |
142-016-EMC |
|
January 2017 |
January 2019 |
May 2019 |
January 11, 2017 |
January 30, 2018 |
|
- Ha'Emek Medical center, Unit of Rheumatology
Afula, Israel - Carmel Medical Center
Haifa, Israel - Tel Aviv Medical Center, Unit pf Rheumatology
Tel Aviv, Israel
|
2 |
NCT03439657 |
Recruiting |
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older |
|
- Biological: HZ/su vaccine GSK1437173A
- Biological: Prevenar13
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of subjects with a vaccine response
- Anti-gE antibody concentrations
- Anti-pneumococcal antibody titers
- (and 7 more...)
|
912 |
All |
50 Years and older (Adult, Senior) |
NCT03439657 |
204487 2017-001220-22 |
|
April 18, 2018 |
March 15, 2019 |
February 5, 2020 |
February 20, 2018 |
April 17, 2018 |
|
- GSK Investigational Site
Weinheim, Baden-Wuerttemberg, Germany - GSK Investigational Site
Wuerzburg, Bayern, Germany - GSK Investigational Site
Essen, Nordrhein-Westfalen, Germany
|
3 |
NCT01573182 |
Recruiting |
Herpes Zoster Vaccine for Bone Marrow Transplant Donors |
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Percentage of transplant recipients with VZV specific T cell proliferation within the first 12 moths post-transplant.
- Donor VZV positivity by PCR and genotype and donor VZV specific T cell response to vaccination
|
10 |
All |
50 Years and older (Adult, Senior) |
NCT01573182 |
VADOVAR |
VZV-Zostavax |
April 2012 |
December 2017 |
December 2018 |
April 6, 2012 |
May 4, 2017 |
|
- Westmead Hospital
Sydney, New South Wales, Australia
|
4 |
NCT03314103 |
Recruiting |
Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age |
|
- Biological: One shot of the varicella-zoster virus vaccine
- Biological: one shot of placebo
|
Interventional |
Phase 3 |
- Jiangsu Province Centers for Disease Control and Prevention
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- The incidence of herpes zoster 30 days after vaccination.
- The incidence of herpes zoster after vaccination.
- The incidence of laboratory-confirmed herpes zoster 30 days after vaccination.
- (and 10 more...)
|
30000 |
All |
40 Years and older (Adult, Senior) |
NCT03314103 |
CS-HZ-2017 |
|
October 6, 2017 |
October 30, 2019 |
December 30, 2019 |
October 19, 2017 |
October 19, 2017 |
|
- Hunan Provincial Center for Disease Control and Prevention
Loudi, Hunan, China - Jiangsu Province Centers for Disease Control and Prevention
Nanjing, Jiangsu, China - Zhejiang Provincial Center for Disease Control and Prevention
Hanzhou, Zhejiang, China
|
5 |
NCT03192319 |
Recruiting |
Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation |
|
|
Interventional |
Not Applicable |
- Seoul National University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Varicella-zoster virus-specific interferon-gamma ELISPOT response
- Antibody titer against varicella-zoster virus
|
120 |
All |
50 Years and older (Adult, Senior) |
NCT03192319 |
H1705030852 |
|
July 1, 2017 |
May 31, 2018 |
May 31, 2018 |
June 20, 2017 |
November 14, 2017 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
6 |
NCT01327144 |
Recruiting |
Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster |
|
- Drug: Famciclovir
- Drug: Aciclovir
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- For efficacy evaluation, a visual analogue scale (VAS) will be used to detect the improvement of symptoms
- Safety will be evaluated by the adverse events occurrences
|
168 |
All |
18 Years to 60 Years (Adult) |
NCT01327144 |
F500EMS1010 |
|
June 2012 |
June 2017 |
July 2017 |
April 1, 2011 |
February 6, 2017 |
|
- Centro de Medicina Reprodutiva Dr Carlos Isaia Filho
Porto Alegre, RS, Brazil - Loema
Campinas, SP, Brazil - CECIP Centro de Estudos Clínicos do Interior Paulista
Jau, SP, Brazil - (and 2 more...)
|
7 |
NCT03134196 |
Recruiting |
Zoster Eye Disease Study |
- Herpes Zoster Ophthalmicus
|
- Drug: Masked Placebo
- Drug: Masked Oral Valacyclovir
|
Interventional |
Phase 4 |
- New York University School of Medicine
- National Eye Institute (NEI)
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to first occurrence of Dendriform epithelial keratitis, Stromal keratitis, Endothelial keratitis or Iritis
|
1050 |
All |
18 Years and older (Adult, Senior) |
NCT03134196 |
16-00463 1U10EY026869 |
ZEDS |
August 23, 2017 |
December 31, 2020 |
December 31, 2020 |
April 28, 2017 |
March 16, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Jules Stein Eye Clinic - UCLA
Los Angeles, California, United States - Pacific Eye Surgeons, Inc.
San Luis Obispo, California, United States - (and 40 more...)
|
8 |
NCT02382588 |
Recruiting |
Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis |
|
- Drug: gancyclovir gel
- Drug: Hypromellose gel
|
Interventional |
Phase 2 |
- Northwestern University
- Bausch & Lomb Incorporated
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Healing based on weekly slitlamp photographs
|
100 |
All |
18 Years to 95 Years (Adult, Senior) |
NCT02382588 |
4321 |
|
January 2015 |
January 2018 |
January 2019 |
March 6, 2015 |
October 17, 2016 |
|
- Northwestern University
Chicago, Illinois, United States
|
9 |
NCT03493776 |
Recruiting New |
Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation |
|
- Biological: VZV subunit vaccine
|
Interventional |
Phase 4 |
- Deepali Kumar
- University Health Network, Toronto
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Cellular immunity to varicella zoster induced by varicella zoster subunit vaccine.
- Humoral immunogenicity to varicella zoster induced by varicella zoster subunit vaccine in lung transplant recipients.
- Humoral immunogenicity to varicella zoster induced by varicella zoster subunit vaccine in post-transplant group vs. pre-transplant group
|
75 |
All |
50 Years and older (Adult, Senior) |
NCT03493776 |
UHN-Shingrix-001 |
|
April 15, 2018 |
September 5, 2019 |
March 5, 2020 |
April 10, 2018 |
April 10, 2018 |
|
- University Health Network, Toronto General Hospital, Multi-Organ Transplant
Toronto, Ontario, Canada
|
10 |
NCT03120962 |
Not yet recruiting |
Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia |
- Herpes Zoster
- Post-herpetic Neuralgia
|
- Drug: Oxycodone
- Drug: Gabapentin
- Drug: Famciclovir
|
Interventional |
Not Applicable |
- Second Affiliated Hospital, School of Medicine, Zhejiang University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients with zoster pain.
- Proportion of patients with zoster pain
- Pain intensity
- (and 2 more...)
|
140 |
All |
50 Years and older (Adult, Senior) |
NCT03120962 |
2017-012 |
|
May 2017 |
May 2020 |
November 2020 |
April 19, 2017 |
April 19, 2017 |
|
|
11 |
NCT02624375 |
Recruiting |
Immune Response to Shingles Vaccination |
|
- Drug: Zoster Vaccine Live
|
Interventional |
Phase 4 |
- University of Washington
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- VZV-specific T-cells
- Levels of VZV-specific CD4 or CD8 T cells in skin
- Adverse Events due to Zostavax
|
50 |
All |
70 Years and older (Senior) |
NCT02624375 |
STUDY00001399 53354 |
|
February 2016 |
December 2018 |
December 2018 |
December 8, 2015 |
April 3, 2018 |
|
- University of Washington Virology Research Clinic
Seattle, Washington, United States
|
12 |
NCT02026089 |
Not yet recruiting |
Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine |
- Persistence of Varicella Immunity
|
- Biological: Varicella vaccine
|
Interventional |
Phase 4 |
- University of Colorado, Denver
- Centers for Disease Control and Prevention
|
Other / U.S. Fed |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Determine the proportion of employees who 5 years previously received varicella vaccine at the time of employment who no longer have varicella-specific antibody.
- Determine the avidity (strength with which the vaccine induced antibody binds to the varicella antigen) of varicella-specific antibody in vaccinated employees.
|
100 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02026089 |
13-1380 |
|
October 2018 |
December 2018 |
December 2018 |
January 1, 2014 |
January 23, 2018 |
|
- Children's Hospital Colorado
Aurora, Colorado, United States
|
13 |
NCT03178747 |
Recruiting |
Tzanck Smear With Methylene Blue Stain for Herpes |
- Herpes Simplex
- Herpes Zoster
- Varicella Zoster
|
- Diagnostic Test: Methylene blue
- Diagnostic Test: Giemsa stain
|
Interventional |
Phase 3 |
- Chulalongkorn University
- Dermatological Society of Thailand
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Sensitivity
- Factors that contribute the results from Methylene blue staining
- Specificity
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT03178747 |
674/59 |
|
March 7, 2017 |
December 7, 2017 |
March 6, 2018 |
June 7, 2017 |
August 4, 2017 |
|
- Division of Dermatology, Faculty of Medicine, Chulalongkorn University
Bangkok, Thailand
|
14 |
NCT02329457 |
Recruiting |
VZV Vaccine for Hematopoietic Stem Cell Transplantation |
- Varicella Zoster Infection
|
- Biological: Zostavax
- Biological: Normal Saline
|
Interventional |
Not Applicable |
- The University of Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Immunological response in donors
- Herpes zoster reactivation
- Adverse reaction
|
120 |
All |
18 Years to 60 Years (Adult) |
NCT02329457 |
HKU 11-174 |
VZIDST |
December 2014 |
March 2018 |
August 2018 |
December 31, 2014 |
July 28, 2017 |
|
- Ivan Hung
Hong Kong, Hong Kong
|
15 |
NCT00492739 |
Recruiting |
Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients |
- Liver Disease
- Immunosuppression
- Varicella
|
- Biological: Vaccination with VZV vaccine
|
Interventional |
Phase 2 Phase 3 |
- University Hospital, Geneva
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of VZV vaccine in OLTx recipients
- Efficacy of VZV vaccine in immunosuppressed OLTx recipients
|
80 |
All |
up to 18 Years (Child, Adult) |
NCT00492739 |
VZVinOLTx |
VZVinOLTx |
June 2007 |
April 2017 |
December 2017 |
June 27, 2007 |
December 30, 2016 |
|
- Children's Hospital of Geneva (HUG)
Geneva, GE, Switzerland
|
16 |
NCT03330171 |
Recruiting |
Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine |
- Measles
- Varicella
- Hepatitis A
|
- Biological: Measles vaccine
- Biological: Hepatitis-A vaccine
- Biological: Varicella vaccine
|
Interventional |
Phase 4 |
- University of Witwatersrand, South Africa
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of participants with seroprotective antibody titres (IgG ≥330 mIU/ml quantified by ELISA) one month post booster measles vaccination
- Number of participants with seroprotective antibody titres (IgG ≥300 mIU/ml quantified by ELISA) one month post varicella vaccination
- Number of participants with seroprotective antibody titres (IgG ≥20 mIU/ml quantified by ELISA) one month post hepatitis-A vaccination
- (and 4 more...)
|
270 |
All |
18 Weeks to 19 Months (Child) |
NCT03330171 |
MV/VV/Hep-AV |
MV/VV/Hep-AV |
April 10, 2017 |
February 2019 |
June 2019 |
November 6, 2017 |
November 6, 2017 |
|
- Chris Hani Baragwanath Academic Hospital; Nrf/Dst Vpd Rmpru
Soweto, Gauteng, South Africa
|
17 |
NCT02689700 |
Recruiting |
Diaplacental Transfer of Anti-HCMV- and Anti-VZV-immunoglobulin G (IgG) -Antibodies at Premature and Mature Newborns |
- Materno-fetal Transfer of Anti-HCMV-IgG
- Materno-fetal Transfer of Anti-VZV-IgG
|
|
Observational |
|
- Johann Wolfgang Goethe University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To measure the concentration of specific HCMV-/VZV-IgG-antibodies in fetal bloodstream depending on gestational age at birth.
- Gauging the concentration of neutralizing IgG-antibodies against HCMV and VZV in fetal bloodstream depending on gestational age at birth.
|
450 |
All |
up to 10 Minutes (Child) |
NCT02689700 |
040713 FRA Mat Fet CMV Antib |
MoChi-HCMV |
July 2013 |
December 2017 |
July 2018 |
February 24, 2016 |
March 7, 2017 |
|
- Clinic of the Johann Wolfgang-Goethe Univeristy
Frankfurt/Main, Hesse, Germany
|
18 |
NCT02477150 |
Recruiting |
Safety and Immunogenicity of a Zoster Vaccine in SLE |
- Systemic Lupus Erythematosus
|
- Biological: Zostavax
- Biological: placebo
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- antibody rise to varicella zoster virus
- safety (incidence of herpes zoster reactivation or chickenpox infection)
- T cell response to VZV
|
90 |
All |
18 Years and older (Adult, Senior) |
NCT02477150 |
NTWC/CREC/15029 |
|
November 2015 |
April 2018 |
September 2018 |
June 22, 2015 |
October 11, 2017 |
|
- Department of Medicine, Tuen Mun Hospital
Hong Kong, China
|
19 |
NCT03239873 |
Recruiting |
Evaluation of Immunogenicity and Safety of VARIVAX™ Passage Extension 34 (PE34) Process in Children (V210-A03) |
|
- Biological: VARIVAX™ PE34 Process
- Biological: VARIVAX™ 2016 Commercial Process
- Biological: M-M-R II™
|
Interventional |
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Varicella Zoster Virus (VZV) Antibody Response Rate
- Varicella Zoster Virus (VZV) Geometric Mean Titer
- Elevated Temperature
- (and 14 more...)
|
600 |
All |
12 Months to 23 Months (Child) |
NCT03239873 |
V210-A03 |
|
October 17, 2017 |
October 9, 2018 |
April 19, 2019 |
August 4, 2017 |
March 8, 2018 |
|
- Alabama Clinical Therapeutics ( Site 0018)
Birmingham, Alabama, United States - Children's Clinic of Jonesboro, PA ( Site 0030)
Jonesboro, Arkansas, United States - Southland Clinical Research Center ( Site 0017)
Anaheim, California, United States - (and 34 more...)
|
20 |
NCT03212885 |
Recruiting |
Stimulation of the Rostral Zona Incerta for Parkinson's Disease |
|
- Device: Deep Brain Stimulation
|
Interventional |
Not Applicable |
- University of Colorado, Denver
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Motor testing
- Dyskinesias
- Cognition
- (and 5 more...)
|
81 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03212885 |
16-1443 |
|
July 3, 2017 |
July 2020 |
October 2020 |
July 11, 2017 |
July 19, 2017 |
|
- University of Colorado
Aurora, Colorado, United States
|
21 |
NCT02538341 |
Recruiting |
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) |
- Rheumatoid Arthritis
- Inflammatory Arthritis
- Arthritis
- (and 5 more...)
|
- Biological: Herpes Zoster Vaccine
- Drug: Placebo
|
Interventional |
Phase 2 |
- University of Alabama at Birmingham
- Oregon Health and Science University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Immunogenicity measured at 6 weeks.
- The clinical effectiveness of the HZ vaccine in reducing longer-term HZ risk
- Estimate vaccine safety
- (and 2 more...)
|
1000 |
All |
50 Years and older (Adult, Senior) |
NCT02538341 |
VERVE-UM1 |
|
May 2016 |
September 2019 |
September 2019 |
September 2, 2015 |
July 19, 2017 |
|
- Rheumatology Associates, PC
Birmingham, Alabama, United States - Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - (and 23 more...)
|
22 |
NCT02775422 |
Recruiting |
Comparison of Serological Test s for the Virus Chicken Pox Virus (VZV) and Correlation With the Patient's Memory of the Infection or Vaccination |
|
- Biological: Serological Test s for the Virus Chicken Pox Virus
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Rate sensitivity and specificity in negative and dubious zone for the assessment of the serology of anti VZV immunity
- frequency of immunity detecting depending on whether the patient remember having varicella, have been in contact with next of kin with varicella or been vaccinated against varicella or not
- Percentage of women accepting the vaccination in case of negative history
|
400 |
Female |
18 Years and older (Adult, Senior) |
NCT02775422 |
2014/08 2014-A00707-40 |
VARI-IMM |
March 2015 |
February 2018 |
February 2018 |
May 17, 2016 |
February 1, 2017 |
|
- Hopital Foch
Suresnes, France
|
23 |
NCT03239665 |
Recruiting |
Vaccination Education Through Pharmacists and Senior Centers (VEPSC) |
- Infectious Disease
- Pneumonia, Bacterial
- Influenza
- Zoster; Herpes
|
- Behavioral: Pharmacist-led Intervention (PHARM)
- Behavioral: Peer-led Intervention (PEER)
|
Interventional |
Not Applicable |
- Rutgers, The State University of New Jersey
- Merck Sharp & Dohme Corp.
- Thomas Jefferson University
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Mean change in knowledge as assessed by the knowledge instrument score
- Mean change in beliefs as assessed by responses to the beliefs inventory
- Cost analysis
- (and 2 more...)
|
316 |
All |
50 Years and older (Adult, Senior) |
NCT03239665 |
Pro20170000208 |
VEPSC |
October 10, 2017 |
August 2018 |
August 2018 |
August 4, 2017 |
November 17, 2017 |
|
- Rutgers University
Piscataway, New Jersey, United States
|
24 |
NCT02687763 |
Recruiting |
Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant |
- RENAL INSUFFICIENCY, CHRONIC
- LIVER FAILURE, ACUTE
- HEART DISEASE
|
|
Interventional |
Phase 1 Phase 2 |
- Medical University of South Carolina
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Varicella IgG Antibody Titer ≥ 1.1 IU/ml
- Measles IgG Antibody Titer ≥ 30AU/ml
- Mumps IgG Antibody Titer ≥ 11AU/ml
- (and 5 more...)
|
45 |
All |
6 Months to 24 Months (Child) |
NCT02687763 |
Pro25854 |
ProQuad® |
December 2015 |
December 2017 |
January 2018 |
February 22, 2016 |
March 23, 2017 |
|
- Medical University of South Carolina, Pediatric Nephrology
Charleston, South Carolina, United States
|
25 |
NCT03421613 |
Recruiting |
3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN) |
|
- Drug: 3VM1001
- Other: Placebo
|
Interventional |
Early Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- The time averaged mean in a standard 100 mm visual analog scale (VAS).
- Adverse Events, serious adverse events, and study discontinuation
- Patient Global Expression of change Scale (PGIC) from baseline (day 0) to the end of each study period.
- (and 2 more...)
|
30 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03421613 |
3VM0416 |
PHN |
March 6, 2017 |
July 30, 2018 |
September 30, 2018 |
February 5, 2018 |
February 6, 2018 |
|
- Medex Healthcare Research, Inc.
Chicago, Illinois, United States - Medex Healthcare Reasearch, Inc.
New York, New York, United States
|
26 |
NCT02633306 |
Recruiting |
Transcranial Magnetic Stimulation for Facial Pain |
- Trigeminal Nerve Injuries
- Post-herpetic Neuralgia
- Facial Pain
- Nervus Intermedius Neuralgia
|
- Device: transcranial magnetic stimulation
|
Interventional |
Not Applicable |
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- visual analogue scale (VAS)
- Hamilton Rating Scale for Depression (HAM-D)
- World Health Organization Quality of Life Abbreviated (WHOQOL-BREF)
|
20 |
All |
18 Years to 110 Years (Adult, Senior) |
NCT02633306 |
1511M80284 |
|
August 2016 |
June 2018 |
December 2018 |
December 17, 2015 |
October 27, 2017 |
|
- University of Minnesota
Minneapolis, Minnesota, United States
|
27 |
NCT01981161 |
Recruiting |
Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis |
|
- Procedure: biological samples and clinical data
|
Observational |
|
- University Hospital, Toulouse
- European Commission
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Disease free patients
- comparing the efficacy of Natalizumab with that of Fingolimod with regard to the annual incidence rate (comparison against the annual incidence rate criterion after 1 year
|
600 |
All |
18 Years to 55 Years (Adult) |
NCT01981161 |
1235207 |
BEST-MS |
November 2013 |
October 2017 |
November 2017 |
November 11, 2013 |
February 23, 2017 |
|
- CHU Besançon
Besancon, France - CHU Bordeaux
Bordeaux, France - CHU Caen
Caen, France - (and 9 more...)
|